Anemia, Iron-Deficiency/diagnosis/physiopathology/therapy; Chronic Disease; Great Britain; Humans; Iron/administration & dosage/adverse effects; Practice Guidelines as Topic
Abstract :
[en] BACKGROUND: The incidence of anaemia is high in many chronic conditions, yet it often receives little attention. SCOPE/METHODS: A panel of international experts with experience in haematology, nephrology, oncology, rheumatology and pharmacy was convened to prepare strategic guidelines. A focused literature search was conducted after key issues had been identified. A series of recommendations was agreed, backed, wherever possible, by published evidence which is included in the annotations. RECOMMENDATIONS: Anaemia is a critical issue for patients with chronic diseases. Healthcare professionals need to recognise that anaemia is a frequent companion of cancer and chronic conditions such as rheumatoid arthritis and heart failure. It reduces patients' quality of life and can increase morbidity and mortality. Anaemia should be considered as a disordered process in which the rate of red cell production fails to match the rate of destruction which leads eventually to a reduction in haemoglobin concentration; this process is common to all chronic anaemias. The aim of anaemia management should be to restore patient functionality and quality of life by restoring effective red cell production. Blood transfusion can elevate haemoglobin concentration in the short term but does nothing to address the underlying disorder; red cell transfusion is, therefore, not an appropriate treatment for chronic anaemia. Patients with anaemia of chronic disease may benefit from iron therapy and/or erythropoiesis stimulating agents (ESAs). Intravenous iron should be considered since this can be given safely to patients with chronic diseases while intramuscular iron causes unacceptable adverse effects and oral iron has limited efficacy in chronic anaemia. CONCLUSION: The management of anaemia calls for the development of a specialist service together with education of all healthcare professionals and transfer of skills from areas of good practice. Improvement in the management of anaemia requires a fundamental change of attitude from healthcare professionals.
Disciplines :
Hematology
Author, co-author :
Cavill, Ivor
Auerbach, Michael
Bailie, George R
Barrett-Lee, Peter
Beguin, Yves ; Centre Hospitalier Universitaire de Liège - CHU > Hématologie clinique
Kaltwasser, Peter
Littlewood, Tim
Macdougall, Iain C
Wilson, Keith
Language :
English
Title :
Iron and the anaemia of chronic disease: a review and strategic recommendations.
Caro JJ, Salas M, Ward A, et al. Anemia as an independent prognostic factor for survival in patients with cancer: a systemic, quantitative review. Cancer 2001;91:2214-21
Locatelli F, Pisoni RL, Akizawa T, et al. Anemia management for hemodialysis patients: Kidney Disease Outcomes Quality Initiative (K/DOQI) guidelines and Dialysis Outcomes and Practice Patterns Study (DOPPS) findings. Am J Kidney Dis 2004;44:27-33
Vogelzang NJ, Breitbart W, Cella D, et al. Patient, caregiver, and oncologist perceptions of cancer-related fatigue: results of a tripart assessment survey. The Fatigue Coalition. Semin Hematol 1997;34:4-12
Berndt E, Kallich J, McDermott A, et al. Reductions in anaemia and fatigue are associated with improvements in productivity in cancer patients receiving chemotherapy. Pharmacoeconomics 2005;23:505-14
Basta SS, Soekirman, Karyadi D, et al. Iron deficiency anemia and the productivity of adult males in Indonesia. Am J Clin Nutr 1979;32:916-25
Selvaratnam RR, de Silva LD, Pathmeswaran A, et al. Nutritional status and productivity of Sri Lankan tea pluckers. Ceylon Med J 2003;48:114-8
Groopman JE, Itri LM. Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst 1999;91:1616-34
World Health Organization 2006. WHO health topics: anaemia. http://www.who.int/topics/anaemia/en/ [last accessed 10 Feb 2006]
Ludwig H, Van Belle S, Barrett-Lee P, et al. The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer 2004;40:2293-306
Knight K, Wade S, Balducci L. Prevalence and outcomes of anemia in cancer: a systematic review of the literature. Am J Med 2004;5:11S-26S
Peeters HR, Jongen-Lavrencic M, Raja AN, et al. Course and characteristics of anemia in patients with RA of recent onset. Ann Rheum Dis 1996;55:162-8
Wilson A, Yu HT, Goodenough LT, et al. Prevalence and outcomes of anemia in rheumatoid arthritis: a systematic review of the literature. Am J Med 2004;116:50S-57S
Laporte J-R, Ibanez L, Vidal X, et al. Upper gastrointestinal bleeding associated with the use of NSAIDs: newer versus older agents. Drug Safety 2004;27:411-20
Vreugdenhil G, Wognum AW, van Eijk HG, et al. Anaemia in rheumatoid arthritis: the role of iron, vitamin B12, and folic acid deficiency, and erythropoietin responsiveness. Ann Rheum Dis 1990;49:93-8
Karhausen T, Anker SD, Doehner W. Anemia in chronic heart failure - clinical and prognostic significance. Curr Med Chem Cardiovasc Hematol Agents 2005;3:297-303
Anand IS, Kuskowski MA, Rector TS, et al. Anemia and change in hemoglobin over time related to mortality and morbidity in patients with chronic heart failure: results from Val-HeFT. Circulation 2005;112:1121-7
Belperio PS, Rhew DC. Prevalence and outcomes of anemia in individuals with human immunodeficiency virus: a systematic review of the literature. Am J Med 2004;116:27S-43S
Guralnik JM, Eisenstaedt RS, Ferrucci L, et al. Prevalence of anemia in persons 65 years and older in the United States: evidence for a high rate of unexplained anemia. Blood 2004;104:2263-8
Ricketts C, Jacobs A, Cavill I. Ferrokinetics and erythropoiesis in man: the measurement of effective erythropoiesis, ineffective erythropoiesis and red cell lifespan using 59Fe. Br J Haematol 1975;31:65-75
Bron D, Meuleman N, Mascaux C. Biological basis of anemia. Semin Oncol 2001;28:1-6
Cavill I. The rejected reticulocyte. Br J Haematol 2005;84: 563-5
Macdougall IC, Cavill I, Hulme B, et al. Detection of functional iron deficiency during erythropoietin treatment: a new approach. Br Med J 1992;304:225-6
Glaspy J, Bukowski R, Steinberg D, et al. Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice [Procrit Study Group]. J Clin Oncol 1997;1915:1218-34
Demetri GD, Kris M, Wade J, et al. Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study [Procrit Study Group]. J Clin Oncol 1998;1916:3412-25
Kaltwasser JP, Arndt U. ACD in inflammatory rheumatic diseases. Anemia of chronic disease. New York: Taylor & Francis; 2005. p. 633-57
Littlewood TJ, Bajetta E., Nortier JWR., et al. Effects of epoetin alfa on hematological parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2001;19:2865-74
Cavill I. The need for a blood transfusion service. Transfus Med 2005;15:257
Cavill I. Reducing blood transfusion. Br Med J 2002;325:655
Peeters HR, Jongen-Lavrencic M, Vreugdenhil G, et al. Effect of recombinant human erythropoietin on anaemia and disease activity in patients with rheumatoid arthritis and anaemia of chronic disease: a randomised placebo controlled double blind 52 week clinical trial. Ann Rheum Dis 2005;55:739-44
Kaltwasser JP, Kessler U, Gottschalk R, et al. Effect of recombinant human erythropoietin and intravenous iron on anemia and disease activity in rheumatoid arthritis. J Rheumatol 2001;28:2340-436
Auerbach M, Ballard H, Trout JR, et al. Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trial. J Clin Oncol 2004;1922:1301-7
Eschbach JW, Egrie JC, Downing MR, et al. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. New Engl J Med 1987;316:73-8
Fishbane S, Ungureanu VD, Maesaka JK, et al. The safety of intravenous iron dextran in hemodialysis patients. Am J Kidney Dis 1996;1928:529-34
Macdougall IC, Tucker B, Thompson J, et al. A randomized controlled study of iron supplementation in patients treated with erythropoietin. Kidney Int 1996;1950:1694-9
Sargent JA, Acchiardo SR. Iron requirements in hemodialysis. Blood Purif 2004;1922:112-23
Martini A, Ravelli A, Di Fuccia G, et al. Intravenous iron therapy for severe anaemia in systemic-onset juvenile chronic arthritis. Lancet 1994;344:1052-4
Cazzola M, Ponchio L, de Benedetti F, et al. Defective iron supply for erythropoiesis and adequate endogenous erythropoietin production in the anemia associated with systemic-onset juvenile chronic arthritis. Blood 1996;87:4824-30
Locatelli F, Aljama P, Barany P, et al. Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 2004;19:1-47
Auerbach M, Witt D, Toler W, et al. Clinical use of the total dose intravenous infusion of iron dextran. J Lab Clin Med 1988;111:566-70
Grasso P. Sarcoma after intramuscular iron injection. Br Med J 1973;16:667
Hamstra RD, Block MH, Schocket AL. Intravenous iron dextran in clinical medicine. J Am Med Assoc 1980;243:1726-31
Feldman HI, Joffe M, Robinson B, et al. Administration of parenteral iron and mortality among hemodialysis patients. J Am Soc Nephrol 2004;1915:1623-32
Hoen B, Paul-Dauphin A, Hestin D, et al. EPIBACDIAL: a multicenter prospective study of risk factors for bacteremia in chronic hemodialysis patients. J Am Soc Nephrol 1998;1909:869-76
Chertow GM, Mason PD, Vaage-Nilsen O, et al. On the relative safety of parenteral iron formulations. Nephrol Dial Transplant 2004;19:1571-5
Bailie GR, Clark JA, Lane CE, et al. Hypersensitivity reactions and deaths associated with intravenous iron preparations. Nephrol Dial Transplant 2005;20:1443-9
Aronoff GR. Safety of intravenous iron in clinical practice: implications for anemia management protocols. J Am Soc Nephrol 2004;15:S99-S106
Weinberg ED. The role of iron in cancer. Eur J Cancer Prev 1996;5:19-36
Hershko C, Link G, Tzahor M, et al. The role of iron and iron chelators in anthracycline cardiotoxicity. Leuk Lymphoma 1993;11:207-14
Cavill I. The hematologist. ASH Newsletter 2005;2:2
